NEW YORK, March 6, 2014 /PRNewswire/ --
Editor Note: For more information about this release, please
scroll to bottom.
Today, Analysts Review released its analysts' notes regarding
Gilead Sciences Inc. (NASDAQ: GILD), Forest Laboratories Inc.
(NYSE: FRX), Thermo Fisher Scientific, Inc. (NYSE: TMO), HCA
Holdings, Inc. (NYSE: HCA), and Nektar Therapeutics (NASDAQ: NKTR).
Private wealth members receive these notes ahead of publication. To
reserve complementary membership, limited openings are available
at: http://www.AnalystsReview.com/register
Gilead Sciences Inc. Analyst Notes
On February 26, 2014, Gilead
Sciences Inc.'s (Gilead) stock declined 0.17%, ending the day at
$83.81. After opening at $84.05, the stock oscillated in a range of
$83.31-$84.50, with total volume of
11.90 million shares. Over the previous three trading sessions,
shares of Gilead have increased by 1.48% compared to the Nasdaq
Composite which gained 0.67% during the same period. The full
analyst notes on Gilead Sciences Inc. are available to download
free of charge at:
http://www.AnalystsReview.com/03062014/GILD/report.pdf
Forest Laboratories Inc. Analyst
Notes
On February 24, 2014, Forest
Laboratories Inc. (Forest) announced the launch of STRIDE (Start
Treatment, Real-time Information, Disease Education) patient
support program that aims to solve all the queries related to
chronic obstructive pulmonary disease (COPD) treatment of patients
prescribed Tudorza® and Daliresp®. The Company informed that STRIDE
program features a dedicated call center staffed by registered
nurses who have been trained to answer questions about each product
and reimbursement specialists prepared to address inquiries related
to insurance coverage and co-pay assistance. Gavin Corcoran, Executive Vice President Global
Medicines Development, commented, "The STRIDE patient support
program is the first of its kind for Forest and reinforces our
commitment to the COPD community. The important information and
services provided through the STRIDE program help patients learn
more about their prescribed COPD treatment and empower them to have
more productive interactions with their healthcare professionals."
The full analyst notes on Forest Laboratories Inc. are available to
download free of charge at:
http://www.AnalystsReview.com/03062014/FRX/report.pdf
Thermo Fisher Scientific, Inc. Analyst
Notes
On February 26, 2014, Thermo
Fisher Scientific, Inc.'s (Thermo
Fisher) stock increased by 0.38%, ending the day at
$124.28. The stock opened at
$123.87 during the session, and then
traded in a range of $123.43-$125.18,
with total volume of 2.62 million shares. Over the previous three
trading sessions, shares of Thermo Fisher Scientific have increased
by 0.89%, compared to the Dow Jones Industrial Average which
advanced 0.59% during the same period. The full analyst notes on
Thermo Fisher Scientific, Inc. are available to download free of
charge at:
http://www.AnalystsReview.com/03062014/TMO/report.pdf
HCA Holdings, Inc. Analyst Notes
On February 26, 2014, HCA
Holdings, Inc.'s (HCA) stock increased by 1.86%, ending the day at
$50.48. After opening at $49.62, the stock vacillated in a range of
$49.41-$50.80, with total volume of
1.32 million. Over the previous three trading sessions, shares of
HCA have increased by 0.94% compared to the Dow Jones Industrial
Average which rose 0.59% during the same period. The full analyst
notes on HCA Holdings, Inc. are available to download free of
charge at:
http://www.AnalystsReview.com/03062014/HCA/report.pdf
Nektar Therapeutics Analyst Notes
On February 26, 2014, Nektar
Therapeutics (Nektar) reported its financial results for Q4 2013
and full year 2013. Revenues of the Company for the quarter
increased to $31.1 million, up 47.3%
YoY, primarily due to increased product shipments to one of the
Company's collaboration partners. Full year 2013 revenues climbed
to $148.9 million, representing a
growth of 83.4% YoY, which the management attributed to a
$25.0 million milestone achieved in
September 2013 upon the acceptance of
the naloxegol MAA filing in Europe
as well as a $10.0 million milestone
achieved upon the initiation of Phase 3 studies for Amikacin Inhale
in April 2013. Net loss for the
quarter narrowed down to $47.7
million, or $0.41 per diluted
share, from $52.9 million, or
$0.46 per diluted share, in Q4 2012;
and the full year 2013 net loss also came down to $162.0 million, or $1.40 per diluted share, from $171.9 million, or $1.50 per diluted share, in full year 2012.
Howard W. Robin, President and CEO
of Nektar, commented, "2014 has the potential to be a
transformative year for Nektar as several of our highly valuable
late-stage programs advance toward approval or filing." The full
analyst notes on Nektar Therapeutics are available to download free
of charge at:
http://www.AnalystsReview.com/03062014/NKTR/report.pdf
About Analysts Review
We provide our members with a simple and reliable way to leverage
our economy of scale. Most investors do not have time to track all
publicly traded companies, much less perform an in-depth review and
analysis of the complexities contained in each situation. That's
where Analysts Review comes in. We provide a single unified
platform for investors' to hear about what matters. Situation
alerts, moving events, and upcoming opportunities.
=============
EDITOR NOTES:
- This is not company news. We are an independent source and our
views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a
best efforts basis and reviewed by Nidhi Vatsal, a CFA
charterholder. However, we are only human and are prone to make
mistakes. If you notice any errors or omissions, please notify us
below.
- This information is submitted as a net-positive to companies
mentioned, to increase awareness for mentioned companies to our
subscriber base and the investing public.
- If you wish to have your company covered in more detail by our
team, or wish to learn more about our services, please contact us
at pubco [at] AnalystsReview.com.
- For any urgent concerns or inquiries, please contact us
at compliance [at] AnalystsReview.com.
- Are you a public company? Would you like to see similar
coverage on your company? Send us a full investors' package to
research [at] AnalystsReview.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort
basis. This document, article or report is prepared and authored by
Analysts Review. An outsourced research services provider
represented by Nidhi Vatsal, CFA, has only reviewed the information
provided by Analysts Review in this article or report according to
the Procedures outlined by Analysts Review. Analysts Review is not
entitled to veto or interfere in the application of such procedures
by the outsourced provider to the articles, documents or reports,
as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to
the accuracy or completeness or fitness for a purpose (investment
or otherwise), of the information provided in this document. This
information is not to be construed as personal financial advice.
Readers are encouraged to consult their personal financial advisor
before making any decisions to buy, sell or hold any securities
mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be
occasioned at the time of printing of this document or any error,
mistake or shortcoming. No liability is accepted by Analysts Review
whatsoever for any direct, indirect or consequential loss arising
from the use of this document. Analysts Review expressly disclaims
any fiduciary responsibility or liability for any consequences,
financial or otherwise arising from any reliance placed on the
information in this document. Analysts Review does not (1)
guarantee the accuracy, timeliness, completeness or correct
sequencing of the information, or (2) warrant any results from use
of the information. The included information is subject to change
without notice.
CFA® and Chartered Financial Analyst® are registered trademarks
owned by CFA Institute.
http://www.AnalystsReview.com/
SOURCE Analysts Review